Par Pharmaceutical (NYSE : PRX) has received final approval from the U.S. Food and Drug Administration for its Abbreviated New ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE